Aim: To determine the incidence of severe hypoglycaemia and its predictors in communitybased patients with type 2 diabetes studied between 2008 and 2013 compared with those in a cohort of patients with type 2 diabetes from the same geographical area assessed a decade earlier.
| INTRODUCTION
The incidence and determinants of severe hypoglycaemia complicating type 2 diabetes are likely to have changed over the past few decades. Incretin-based drugs, sodium-glucose co-transporter-2 (SGLT2) inhibitors and more pharmacokinetically advantageous basal insulin formulations, all therapies associated with a relatively low risk of hypoglycaemia, 1, 2 have been introduced recently. In large-scale trials reported between 1998 and 2009, the potential benefits of intensive glycaemic management for complications such as myocardial infarction and diabetic nephropathy were offset by an overall neutral effect on mortality, but an increase in severe hypoglycaemia. 3 These findings have led to evidence-based recommendations that there should be individualization of glycaemic targets reflecting, in part, the potential adverse impact of low blood glucose concentrations, 4, 5 so that treatment can be better tailored to improve safety without sacrificing long-term micro-and macrovascular benefits. In addition, the incidence of chronic renal disease, a strong risk factor for severe hypoglycaemia, 6 appears to be declining in younger age groups but increasing in the elderly with type 2 diabetes. 7 Identification of clinically important, and especially modifiable, predictors of severe hypoglycaemia in type 2 diabetes is an essential part of patient management. In light of recent changes in available therapies, treatment strategies and comorbidities, we have reassessed the incidence and predictors of severe hypoglycaemia in a well characterized community-dwelling urban patient cohort around a decade after an initial study with the same aims conducted in the same catchment area. 8 Although the consensus view of the definition of severe hypoglycaemia is that there should be psychomotor impairment that precludes self-treatment, 9 ,10 the reporting of such events is known to be unreliable. 6, 11 We therefore used an objective definition of events based on the documented need for emergency health services both in our initial study 8 and the present analyses.
| PARTICIPANTS AND METHODS

| Participants
Our original severe hypoglycaemia study 8 advertising through local media, pharmacies, optometrists and networks of healthcare professionals, and third-party mail-outs to registrants of the Australian National Diabetes Services Scheme and the National Diabetes Register. 13 Details of recruitment as well as sample characteristics including classification of diabetes types and nonrecruited patients have been published elsewhere. 12, 13 In the FDS1, 2258 people with diabetes were identified from a population of~120 000, and 1426 (63%) were recruited, of whom 1294 (91%) had clinically defined type 2 diabetes. Given that complete databases from which severe hypoglycaemic events were ascertained were only available 6 years after the FDS1 started, the analyses were restricted to a subset of 616 participants with type 2 diabetes. 8 In the FDS2, 4639 people with diabetes were identified from a population of~157 000, and 1668 (36%) were recruited, together with 64 former participants in the FDS1 who had moved out of the area. Altogether, 1732 (36%) were recruited to the FDS2, of whom 1551 (90%) had type 2 diabetes. All relevant databases were available for each of the FDS2 participants from the time of study entry.
| Baseline and annual assessments
In both Fremantle Diabetes Study (FDS) phases, assessment at study entry and at each annual (FDS1) or biennial (FDS2) review included a comprehensive questionnaire, physical examination and biochemical tests. In addition to details of all medical conditions and their management, demographic, socio-economic and lifestyle data were recorded.
Participants were requested to bring all medications to each visit and details, including doses, were recorded. In the case of incomplete medication data, full details were collected by telephone and/or review of hospital case notes. Biochemical tests were performed on fasting blood and urine samples using standard automated methods in a single nationally accredited laboratory. 12 In the FDS2, comprehensive postal questionnaires were sent to participants in the years between face-to-face assessments.
Complications were identified using standard definitions.
14 Microalbuminuria was defined as a urine albumin:creatinine ratio ≥ 3.0 mg/mmol, and renal impairment was assessed from the estimated glomerular filtration rate (eGFR). 15 Neuropathy was defined using the clinical portion of the Michigan Neuropathy Screening
Instrument. Retinopathy was defined as one microaneurysm in either eye or worse and/or evidence of previous laser treatment on fundus photography, and/or more detailed ophthalmological data in patients assessed for photocoagulation. Autonomic neuropathy was defined as orthostatic hypotension (a fall of ≥20 mmHg in systolic blood pressure or ≥10 mmHg diastolic blood pressure on standing). Participants were classified as having coronary heart disease if there was a history of myocardial infarction, angina, coronary artery bypass grafting or angioplasty, and as having cerebrovascular disease if there was a history of stroke and/or transient ischaemic attack. Peripheral arterial disease was defined as an ankle brachial index ≤0.90 or the presence of a diabetes-related lower-extremity amputation. The plasma Nterminal pro-B-type natriuretic peptide concentration (NT-proBNP) was measured by commercial assay with inter-day imprecision ≤4.0%
at concentrations up to 406 pg/mL and a limit of detection of 5 pg/mL.
| Ascertainment of severe hypoglycaemia
As in the FDS1, 8 severe hypoglycaemia in the FDS2 was defined as an episode in which a participant with a subnormal blood/plasma/serum glucose required health service use and hypoglycaemia was the primary diagnosis. Relevant data were accessed from three health ser- or ICD-10 codes was required. For (a), episodes were extracted from the Western Australia Data Linkage System (WADLS) 16 and the case notes were reviewed where possible to validate coding and obtain other data including the blood glucose concentration at the time, the treatment given, blood glucose-lowering and other prescribed medications, comorbidities and outcome.
| Statistical analysis
The computer packages SPSS (Tables 1 and 2 ), all results include imputed data.
Cox proportional hazards modelling with backward conditional variable entry (P < 0.05) and removal (P > 0.05) was used to determine independent predictors of the first episode of severe hypoglycaemia during follow-up from clinically plausible baseline variables, with P < 0.20 in bivariate analyses ( Table 2 ). Predictors of frequency of severe hypoglycaemia were assessed using Poisson, negative binomial (NB), zero-inflated Poisson (ZIP) and zero-inflated negative binomial (ZINB) regression models. 17 To allow for the skewed distribution (Table 2) were entered into multiple logistic regression models using forward conditional modelling (P < 0.05 for entry, P > 0.05 for removal) to determine the independent associates of at least one episode of subsequent severe hypoglycaemia. These variables were entered into the ZIP and ZINB inflate models, which predict whether or not a participant would be a certain zero (those assumed never to be at risk of severe hypoglycaemia), while the count models were constructed from consideration of all other available clinically plausible variables. If the likelihood ratio test of ln(α), where α is the dispersion parameter, was significant, then the null hypothesis (that the NB model is no better than the Poisson model) was rejected. The
Vuong test was used to compare the ZIP with the standard Poisson model and the ZINB with the standard NB model. 18 If the Vuong test was significant, the null hypothesis (that the zero-inflated model is no better than the standard one) was rejected.
For the primary aim of identifying predictors of severe hypoglycaemia in the FDS2, with first episode of severe hypoglycaemia during follow-up as the outcome, a fixed sample size of 1551, 80%
power and a 5% level of significance, a hazard ratio of ≥1.42 (or, if inverse, ≤0.73) could be detected for a potential predictor with a prevalence of ≥10% (e.g. current smoking), ≥1.65 (or ≤ 0.65) for one with prevalence ≥5% (e.g. eGFR 30-44 mL/min/1.73m 2 ), and ≥ 1.89
(or ≤ 0.60) for one with prevalence ≥3% (e.g. history of severe hypoglycaemia).
3 | RESULTS
| Baseline participant characteristics
The 1551 participants with type 2 diabetes recruited to the FDS2 had a mean age of 65.7 years, 51.9% were men, diabetes had been diagnosed a median 9.0 years previously, and the median glycated haemoglobin (HbA1c) concentration was 51 mmol/mol (6.8%). In total, 350 participants in the FDS2 (22.6%) were insulin treated (with or without sulphonylureas), 475 (30.6%) were taking sulphonylureas with or without insulin, and 79 (5.1%) were taking both insulin and a sulphonylurea. The majority of participants on sulphonylurea therapy were taking gliclazide (75.8%), with smaller percentages on glimepiride, glibenclamide or glipizide. The key baseline characteristics of the participants in the FDS2 and those of the 616 participants with available data relating to severe hypoglycaemic events from the FDS1 are summarized in Table 1 . The main differences were that the participants in the FDS2 were an average of just over 1 year younger and they had a mean body mass index that was 1.4 kg/m 2 higher than the FDS1 sample. They were also more likely to be insulin treated and less likely to have chronic renal impairment. ).
| Episodes of severe hypoglycaemia
In both the FDS1 and FDS2, the incidence of severe hypoglycaemia was increased to a similar extent when participants were treated with a sulphonylurea and especially insulin, while regimens involving basal-bolus and pre-mixed insulin were more likely to cause severe hypoglycaemia than basal insulin alone in the FDS2 (Figure 1 ).
| Predictors of first episode of severe hypoglycaemia
The baseline characteristics of the participants in the FDS2 who experienced at least one episode of severe hypoglycaemia during followup compared with those who did not are summarized in Table 2 .
Those with incident severe hypoglycaemia were older, less likely to be of Southern European ethnic background, and less likely to be married, and they had a lower alcohol consumption than those without severe hypoglycaemia. They had a longer diabetes duration and higher HbA1c concentration, were more likely to be taking sulphonylureas and/or insulin, and to have a history of severe hypoglycaemia. They were more likely to have more micro-and macrovascular complications of diabetes, and to be taking β-blockers and/or anticoagulants.
Their plasma NT-proBNP concentrations and serum aspartate transaminase to alanine transaminase ratios were higher than those of participants without incident severe hypoglycaemia.
The selection of plausible predictors of severe hypoglycaemia was based on bivariate differences in Table 2 fibrates and allopurinol), low eGFR, high urinary albumin:creatinine ratio, peripheral neuropathy, heart failure (through measurement of plasma NT-proBNP concentrations), 22 polypharmacy (≥5 prescribed medications), and any hospitalization in the previous 12 months. Data used in the multivariate models were missing for 9% of participants (on average one variable was missing for each of these participants; nine variables had missing data).
In a Cox proportional hazards model of incident severe hypoglycaemia, older age, education beyond primary level, alcohol consumption, current smoking, treatment with sulphonylurea and/or insulin, a history of severe hypoglycaemia, retinopathy, an eGFR <60 mL/min/1.73 m 2 (with an inverse association with the degree of reduction in eGFR), and ln(NTproBNP) independently predicted the time to first episode (Table 3) .
| Predictors of frequency of severe hypoglycaemia
The NB regression model fitted the data best on inspection and statistical analysis showed the NB model to be superior to the Poisson 
| DISCUSSION
The present data show that there was no statistically significant reduction in either incident severe hypoglycaemia requiring emergency health service utilisation or the frequency of such episodes in individual participants over the 10 years between the two FDS phases conducted in an urban Australian setting. Two well-established risk factors for incident severe hypoglycaemia, specifically a history of severe hypoglycaemia and renal impairment, 6 were strong independent predictors in both the FDS2 and FDS1. 8 Treatment with insulin and/or its secretagogues (duration of insulin therapy in FDS1 8 and both insulin and sulphonylurea therapy in FDS2) was a risk factor.
Education beyond primary school level independently predicted the time to first episode in both phases, while, in the FDS2, older age, current smoking and plasma NT-proBNP were other risk factors. In the simplest model of predictors of the frequency of severe hypoglycaemia, all of the independent risk factors except smoking were shared with those for incident severe hypoglycaemia.
The crude incidence of severe hypoglycaemia in the FDS2 (1.34/100 participant-years) was not significantly different from that in the FDS1 (1.67/100 participant-years) 8 and, as reported previously after allowing for differences in populations and ascertainment of events, 8 consistent with the overall incidence in type 2 diabetes found in other epidemiological studies. [23] [24] [25] When much higher rates have been reported, 26, 27 this has been when severe episodes have been ascertained in only insulin-treated patients (who also had relatively high rates in the present study, especially those on pre-mixed or basal-bolus regimens) and/or from those requiring second-party assistance rather than the much more restrictive criteria used in the present study.
Given that SGLT2 inhibitor therapy was only available at the end of the FDS2 follow-up period, the main changes in therapies for type 2 diabetes between FDS1 and FDS2 (after 2006) were the introduction of dipeptidyl peptidase-4 inhibitors, exenatide and glargine insulin. There were few participants on incretin-based therapies in the FDS2 because of their relative novelty and restrictions associated with their government-subsidized use (Table 1) . Reflecting this situation, a similar proportion of participants in the FDS1 (54.0%) were on insulin or secretagogues (largely sulphonylureas) at study entry 28 compared with the FDS2 (53.2%), even though more participants in the FDS2 were on insulin (22.6% vs 12.1%) and fewer were on secretagogues than in the FDS1. This latter difference might partly reflect the availability of glargine during the FDS2 but glargine does not significantly attenuate the risk of severe hypoglycaemia compared with conventional NPH insulin that was the most commonly prescribed basal insulin in the FDS1. 29 Considering these various factors, it is not surprising that rates of severe hypoglycaemia did not fall significantly between the FDS1 and the FDS2. History of hospitalization for severe hypoglycaemia was a strong independent predictor of the first episode in both FDS phases during follow-up. Impaired awareness of hypoglycaemia is a consequence of severe hypoglycaemia and predicts its subsequent occurrence. 20, 36 As in the FDS1, 8 we did not collect data on autonomic warning symptoms, but prior severe hypoglycaemia may have attenuated neuroendocrine defences in some participants in the FDS2 and contributed to a later severe episode. 37 As also found in FDS1 analyses, 8 the present data confirm the importance of renal impairment as a risk factor for severe hypoglycaemia. 24 There was a proportionate increase in risk as the eGFR declined so that participants with stage 4 or 5 renal disease were approaching five times as likely to experience incident severe hypoglycaemia as those with normal renal function. There was similarly a graded increase in severe hypoglycaemia risk with treatments that increase circulating insulin concentrations from an approximate doubling for regimens that included sulphonylureas to approaching a four times increase with complex insulin-based regimens. While consistent with some 38, 39 but not all 20 studies, duration of insulin treatment was a predictor in the FDS1. 8 This variable was not reliably ascertained in the FDS2 since follow-up started from study entry rather than at least 2 years after enrolment in the FDS1
allowing treatment history to be better characterized.
There was a significant association between peripheral neuropathy but not autonomic neuropathy and incident severe hypoglycaemia in the FDS1 8 that may have reflected the confounding effects of the close relationship between these neurological complications. 40 Microvascular complications cluster within individuals with type 2 diabetes because of shared pathophysiology 41 and have all been associated with severe hypoglycaemia in large population-based studies of type 2 diabetes. 42 Despite strong bivariate associations between both peripheral sensory neuropathy and retinopathy and incident severe hypoglycaemia in the present study, neither was an independent risk factor in multivariable models. This may have reflected the availability of plasma NT-proBNP concentrations in the FDS2 but not the FDS1.
Heart failure has been shown to be a risk factor for severe hypoglycaemia in population-based studies of diabetes of unspecified type 32 through putative mechanisms that include blunting of autonomic counter-regulatory responses by the disease itself or treatment with β-blockers. 19, 43 Consistent with these observations, our data show that the potent biomarker of heart failure, plasma NT-proBNP, 22 was also a predictor of subsequent severe hypoglycaemia independently of β-blocker use, which, although greater in those FDS2 participants with incident severe hypoglycaemia compared with those without in bivariate analyses, was not a significant predictor in the final Cox model. In addition, hypoglycaemia per se does not increase plasma NT-proBNP. 44 We suggest, therefore, that a raised plasma NT-proBNP concentration should be taken into consideration when assessing future severe hypoglycaemia risk in type 2 diabetes, especially as the combination of heart failure and severe hypoglycaemia may carry a particularly grave prognosis. 45 Low plasma NT-proBNP concentrations are associated with insulin resistance, dysmetabolism and increased risk of future diabetes in preclinical and population studies, 46 implying that high circulating NTproBNP levels might themselves reduce glycaemia. Indeed, chronic BNP infusion in db/db mice induces a significant reduction in blood glucose levels. 47 There is, however, also epidemiological evidence that the inverse relationship between NT-proBNP and glycaemia is attenuated at high NT-proBNP concentrations. 48 Whether NT-proBNP has a direct metabolic role in increasing the risk of severe hypoglycaemia is thus speculative.
Smoking is known to reduce insulin clearance, 49 a mechanism that has been suggested as contributing to the increased risk of severe hypoglycaemia in adults with type 1 diabetes who smoke. 50 These studies are consistent with a more than doubling of the risk of incident severe hypoglycaemia in FDS2 participants with type 2 diabetes who were current smokers compared with those who were not. There may also be a contribution from the suboptimal self-care and inadequate support networks that are associated with smoking, 51 factors that could increase the risk of hypoglycaemia independently of a direct effect on insulin metabolism.
Older age is associated with an increased risk of severe hypoglycaemia in type 2 diabetes 52,53 and the present study shows a 40% increase in risk for each decade increase in age. We found that higher educational attainment was a risk factor for incident severe hypoglycaemia in the FDS1 8 and for the incidence and frequency of such episodes in the present study. We postulated previously that better educated Australian patients may be more aware of the chronic vascular sequelae of poor glycaemic control and consequently engage in self-management practices that increase the risk of severe hypoglycaemia, while those with lower educational attainment may not access health services, and thus intensive management, as readily as those who are well educated. 8 Other factors associated with frequency of severe hypoglycaemia in an NB model were the same variables that predicted first occurrence including increased alcohol consumption. It is of interest that FDS2 participants with incident severe hypoglycaemia consumed significantly less alcohol than those without in bivariate analysis. This implies that there is a sub-group of patients with relatively high intermittent alcohol consumption that puts them at risk of recurrence through alcohol-associated inhibition of gluconeogenesis, an impaired counter-regulatory response and attenuated hypoglycaemic awareness. 54, 55 In the FDS1 we found that, in those who were likely to experience recurrent hypoglycaemia, there was a positive relationship with HbA1c. 8 This has also been observed in other studies 23, 56 and may reflect unstable control, which includes unpredictable swings but a tendency to higher overall blood glucose levels as an attempt at compensatory self-protection. The fact that we did not observe this relationship in the FDS2 may reflect the increased availability of medications (incretin-based therapies, SGLT2 inhibitors, and especially novel basal insulin formulations) that may be particularly useful in these patients. It is also possible that changes in available treatment and management strategies attenuated the contribution of the angiotensin-converting enzyme DD genotype to incident and recurrent severe hypoglycaemia that was observed in the FDS1 57 but not in the FDS2.
The present study had limitations. As in the original FDS1 analyses and other observational studies, 23, 24 we did not include episodes of hypoglycaemia requiring second-party assistance but not health service use because they may be unreliable. 6, 11 Our ascertainment was an underestimate of the true incidence of severe hypoglycaemia as a result. 58 There may have been changes in diabetes management, other than use of new therapies, between the FDS1 and FDS2 (such as the institution of individualized glycaemic targets) that may have influenced the risk of severe hypoglycaemia, but we had comprehensive data including variables such as HbA1c that would reflect such changes. The strengths of the present study include the range of factors available for multivariable analysis and relatively objective severe hypoglycaemia ascertainment.
The present study used a pragmatic metric for severe hypoglycaemia (that requiring emergency health service utilization) to show that there have been no significant temporal changes in its incidence and frequency over the 15 years between FDS phases. The predictors of incident severe hypoglycaemia in the FDS1 and FDS2 were similar but current smoking and plasma NT-proBNP were independent risk factors in the FDS2 that were not observed or measured in the FDS1.
In the case of recurrent episodes in the FDS2, all of the risk factors were those for incident severe hypoglycaemia except smoking. These data could be used to inform contemporary clinical management and highlight the need for updated analyses of the incidence and predictors of severe hypoglycaemia against a background of temporal changes in patient characteristics, management algorithms and blood glucose-lowering therapies. 
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